P914 - TOLERANCE AND COMPLIANCE TO FIBRE CONTAINING ORAL NUTRITIONAL SUPPLEMENTS (ONS) IN PATIENTS AT RISK OF DISEASE RELATED MALNUTRITION (DRM)

P914

TOLERANCE AND COMPLIANCE TO FIBRE CONTAINING ORAL NUTRITIONAL SUPPLEMENTS (ONS) IN PATIENTS AT RISK OF DISEASE RELATED MALNUTRITION (DRM)

A. Gagnon^1,*, A. O'Callaghan¹, C. Rouws¹, Y. Luiking¹

¹Danone Research & Innovation, Utrecht, Netherlands

Rationale: Fibre containing enteral formulas can normalize bowel function and reduce diarrhoea and constipation¹. Confirming the gastrointestinal (GI) tolerance of fibre containing ONS is important to promote compliance. This multi-country study investigated GI tolerance and compliance of two fibre containing ONS.

Methods: A 4 week, randomized, controlled, single-blind, study was performed. Patients with medium or high risk of DRM or already taking ONS received 1-2 servings daily of either a 125 ml ONS, n=25, (Fortimel Compact Fibre®), or a 200 ml ONS, n=25, (Fortimel Energy Multifibre®). Both products contained 300 kcal, 12g protein, and 4.5g fibre per serving. GI symptoms, stool frequency and incidence of liquid stools were self-reported at baseline, day 14 and 28. Symptom severity was reported as absent, mild, moderate or severe. Compliance (% consumed vs prescribed; mean ± SEM) was assessed daily. Statistical analysis by Non-parametric Mann-Whitney U test (stool frequency, compliance) or Fisher’s Exact test (liquid stools & GI symptoms).

Results: GI symptoms and changes from baseline were not different between groups at any time point (P>0.05). There was a larger increase in the change in mean daily stool frequency from baseline in the 125 ml group vs the 200 ml group (P=0.008). However, mean daily stool frequency was not different between groups (P=0.949) and varied between 0-1 per day for most subjects. Incidence of liquid stools and diarrhoea (≥3 liquid stools/day) did not differ between groups (P=0.549). Mean compliance over the total intervention was not different between Fortimel Compact Fibre (91.7% ±3.2) vs Fortimel Multifibre (94.2%±3.4) (P=0.870).

Conclusion: 125 ml & 200 ml fibre containing ONS were well tolerated, and patients at risk of DRM complied similarly to the intervention with both ONS.

References:  

        1. Elia et al. Aliment Pharmacol Ther, 2008; 27(2).

Disclosure of Interest: A. Gagnon Other: Employee of Danone Research & Innovation, A. O'Callaghan Other: Employee of Danone Research & Innovation, C. Rouws Other: Employee of Danone Research & Innovation, Y. Luiking Other: Employee of Danone Research & Innovation